Puscasu, Adelina
Zanchetta, Martina
Posocco, Bianca
Bunka, David
Tartaggia, Stefano
Toffoli, Giuseppe
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (12214)
Article History
Received: 15 September 2020
Revised: 16 November 2020
Accepted: 20 November 2020
First Online: 6 January 2021
Compliance with ethical standards
:
: D. Bunka is a Co-founder and Director of Aptamer Group and therefore has financial interest in Aptamer Group Ltd. A. Puscasu, M. Zanchetta, B. Posocco, S. Tartaggia, and G. Toffoli have no conflicts to declare regarding the publication of this manuscript.
: Plasma samples were collected from patients enrolled in a phase Ib clinical study (CRO-2009-25, Prot. n. 0041793(09)-PRE.21-984) approved by the ethics committee of CRO-National Cancer Institute of Aviano (Italy) and by Istituto Superiore di Sanità (ISS, Italy), which was conducted according to the principles expressed in the Declaration of Helsinki. Informed consent was obtained from all participants involved in the study.
: Control human plasma stabilized with K<sub>2</sub>EDTA for the preparation of daily standard calibration curves and quality control (QC) samples was obtained from healthy volunteers and was provided by the Transfusion Unit of the Centro di Riferimento Oncologico di Aviano (CRO), Italy.